Antimicrobial susceptibility of <i>Stenotrophomonas maltophilia</i> from United States medical centers (2019–2023)
We evaluated the antimicrobial susceptibility of 1,400 clinical isolates of <i>Stenotrophomonas maltophilia</i> consecutively collected from United States medical centers in 2019-2023. Aztreonam-avibactam (MIC<sub>50/90</sub>, 2/4 µg/mL; 99.6% inhibited at ≤8 µg/mL) was the most active compound, followed by trimethoprim-sulfamethoxazole (MIC<sub>50/90</sub>, ≤0.12/0.5 µg/mL; 96.9% susceptible), minocycline (MIC<sub>50/90</sub>, 0.5/2 µg/mL; 89.2% susceptible), and levofloxacin (MIC<sub>50/90</sub>, 1/8 µg/mL; 78.9% susceptible). Aztreonam-avibactam retained potent activity against isolates not susceptible to trimethoprim-sulfamethoxazole, minocycline, and/or levofloxacin (99.3%-100.0% inhibited at ≤8 µg/mL).
Authors
- Timothy B Doyle (ORCID: https://orcid.org/0000-0002-1083-8742)
- S J Ryan Arends (ORCID: https://orcid.org/0000-0001-5961-6238)
- Hélio S. Sader (ORCID: https://orcid.org/0000-0001-7022-6644)
- Mariana Castanheira
Institutions
- JMI Laboratories (US)
Publication Details
- Journal
- Antimicrobial Agents and Chemotherapy
- Published
- 2025-03-06
- DOI
- https://doi.org/10.1128/aac.00124-25
- Citations
- 10
- Primary Topic
- Infections and bacterial resistance
- Type
- article
- Field-Weighted Citation Impact
- 17.98